Eton Pharmaceuticals: Buy Rating Affirmed on Khindivi’s FDA Approval and Strong Revenue Growth Prospects

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report), boosting the price target to $35.00.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors including the recent FDA approval of Khindivi, a new oral formulation of hydrocortisone for pediatric patients with adrenal insufficiency. This approval is expected to significantly enhance Eton Pharmaceuticals’ adrenal insufficiency franchise, as Khindivi addresses existing needs for patients who have difficulty with current granular formulations. The drug’s ease of administration and lack of special handling requirements position it to potentially become the preferred choice among caregivers and physicians.
Furthermore, Eton Pharmaceuticals has demonstrated strong commercial execution with the launch of three new drugs in the first half of 2025, suggesting a promising revenue inflection year. The analyst projects a substantial year-over-year revenue growth of 91% for 2025, driven by the anticipated rapid adoption of Khindivi. This optimistic outlook is reflected in the updated 12-month price target of $35 per diluted share, up from the previous target of $33, supported by a risk-adjusted net present value analysis.

Ramakanth covers the Healthcare sector, focusing on stocks such as Nanobiotix, Delcath Systems, and ALX Oncology Holdings. According to TipRanks, Ramakanth has an average return of 1.9% and a 36.87% success rate on recommended stocks.

In another report released on May 16, B.Riley Financial also maintained a Buy rating on the stock with a $26.00 price target.